



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/674,853	11/07/2000		Fulvio Mavilio	1303-110	5693
23117	7590 08/26/2004		EXAMINER		
NIXON &			WEHBE, ANNE MARIE SABRINA		
1100 N GLE 8TH FLOOR	-	,	ART UNIT	PAPER NUMBER	
ARLINGTO	N, VA 2	2201-4714	1632		

DATE MAILED: 08/26/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)		
09/674,853	MAVILIO, FULVIO		
Examiner	Art Unit		
Anne Marie S. Wehbe	1632		

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 14 May 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.
PERIOD FOR REPLY [check either a) or b)]
a) The period for reply expires <u>6</u> months from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
1. A Notice of Appeal was filed on 14 July 2004. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. The proposed amendment(s) will not be entered because:
(a) Ithey raise new issues that would require further consideration and/or search (see NOTE below);
(b) ☐ they raise the issue of new matter (see Note below);
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) they present additional claims without canceling a corresponding number of finally rejected claims. NOTE: see attached
3. ☑ Applicant's reply has overcome the following rejection(s): The rejection under 35 U.S.C. 102(a).
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: see attached.
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed:
Claim(s) objected to:
Claim(s) rejected: <u>11, 13-22</u> .
Claim(s) withdrawn from consideration:
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)
10. Other:

Application/Control Number: 09/674,853

Art Unit: 1632

Attachment to Advisory Action

2. cont. The proposed claim amendments would amend the claims to recite an ex vivo method of

Page 2

gene therapy not previously claimed. The claims under rejection were directed to methods of

myogenic conversion of dermal fibroblasts ex vivo and did not include a therapeutic step of

administering the genetically modified dermal fibroblasts to muscle tissue in vivo. This is a new

issue which would require further search and consideration.

5. cont. Applicant's arguments regarding the rejections of the claims under 35 U.S.C. 103 are

directed to the proposed amended claims. Since the proposed claim amendments have not been

entered, applicant's arguments are not persuasive in overcoming the grounds of rejection over

pending claims 11, and 13-22.

Any inquiry concerning this communication from the examiner should be directed to

Anne Marie S. Wehbé, Ph.D., whose telephone number is (571) 272-0737. The examiner can be

reached Monday- Friday from 10:30-7:00 EST. If the examiner is not available, the examiner's

supervisor, Amy Nelson, can be reached at (571) 272-0804. For all official communications, the

technology center fax number is (703) 872-9306. For informal, non-official communications

only, the examiner's direct fax number is (571) 273-0737.

Dr. A.M.S. Wehbé

ANNE M. WEHBE' PH.D

PRIMARY EXAMINER